WO2012072014A1 - Timbre transdermique prévenant la volatilisation de la rasagiline - Google Patents

Timbre transdermique prévenant la volatilisation de la rasagiline Download PDF

Info

Publication number
WO2012072014A1
WO2012072014A1 PCT/CN2011/083040 CN2011083040W WO2012072014A1 WO 2012072014 A1 WO2012072014 A1 WO 2012072014A1 CN 2011083040 W CN2011083040 W CN 2011083040W WO 2012072014 A1 WO2012072014 A1 WO 2012072014A1
Authority
WO
WIPO (PCT)
Prior art keywords
rasagiline
patch
transdermal patch
content
backing layer
Prior art date
Application number
PCT/CN2011/083040
Other languages
English (en)
Chinese (zh)
Inventor
林佳亮
陈皓
刘泽荣
樊斌
张涛
邓杰
Original Assignee
重庆医药工业研究院有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 重庆医药工业研究院有限责任公司 filed Critical 重庆医药工业研究院有限责任公司
Publication of WO2012072014A1 publication Critical patent/WO2012072014A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the invention belongs to the field of pharmaceutical preparations, and particularly relates to a transdermal patch for preventing rasagiline volatilization.
  • the backing layer material used for the transdermal patch has an oxygen transmission rate of not more than 100 cm 3 /m 2 /24h.
  • the transdermal patch can effectively reduce the content of rasagiline due to volatilization from the backing layer. Background technique
  • Rasagiline is an irreversible selective monoamine oxidase B (MAOB) inhibitor that can be used to treat or prevent Parkinson's disease, Alzheimer's disease, depression, ADHD, restless legs syndrome, multiple sclerosis And withdrawal syndrome.
  • MAOB monoamine oxidase B
  • CN101032474A discloses a rasagiline transdermal patch for treating or preventing a neurological condition, the patch comprising an inert support layer that does not chemically interact with the matrix component, one containing rasagiline or a matrix layer of a pharmaceutically acceptable salt and a protective layer to be removed before use, the matrix layer being an organic polymer material and an inorganic or organic substance
  • the material is a drug-loading reservoir of a conditioning agent comprising rasagiline; the matrix also contains one or more substances that promote transdermal absorption of rasagiline.
  • the backing layer may be selected from a foil or a composite film such as polyethylene or polypropylene, or a nonwoven fabric. In a specific embodiment, the backing material is a medical nonwoven fabric.
  • CN101606923A discloses a stable controlled translation of a rasagiline transdermal patch comprising: a effective amount of rasagiline and a pharmaceutically acceptable salt thereof, b at least one hydrophilic polymerization
  • the substrate, c the pH of the patch is no more than 7.0.
  • the preferred pH is between not less than 3.0 and not more than 6.5.
  • the commonly used backing layer has different densities of different oxygen permeability, and different backing materials due to different materials, different materials, different materials, different processing methods and different thicknesses, and the backing material.
  • the oxygen transmission rate has a great influence on the quality of rasagiline in the patch. Rasagiline is volatile at higher temperatures and can pass through a backing layer with a higher oxygen transmission rate, especially It is at the higher temperature of the production, storage process and application stage, resulting in the loss of rasagiline from the volatilization of the backing.
  • Rasagiline is a secondary amine alkaloid with a free base having a melting point of 37 ° C ⁇ K) ° C and a boiling point above 120 ° C. When tested, it was unexpectedly found that rasagiline is close to the body surface. At a temperature of 32 ° C, there is a strong volatility, resulting in a decrease in the content of rasagiline in the patch.
  • the patch attached to the human skin will cause rasagiline to volatilize from the backing layer in the air, thereby reducing the content of rasagiline in the patch, affecting the therapeutic effect.
  • a backing of a suitable material for which the present invention has been accomplished.
  • the invention finds that selecting a backing layer material with an oxygen permeability of not more than 100 cm 3 /m 2 /24h to prepare a patch can effectively solve the problem of volatile loss of rasagiline, and ensure the quality and efficacy of the transdermal patch. . Summary of the invention It is an object of the present invention to provide a rasagiline transdermal patch which is effective in preventing or minimizing the loss of rasagiline from the backing layer to maintain a sustained therapeutic effect.
  • a rasagiline transdermal patch comprising a rasagiline or a pharmaceutically acceptable salt thereof, a matrix and an inert backing layer, characterized in that: the backing layer has an oxygen transmission rate of not more than 100 cm 3 /m 2 /24h.
  • the material of the backing layer is selected from any one or more selected from the group consisting of aluminum, polyester, polyethylene, polyvinyl acetate, and polypropylene.
  • the material of the backing layer is selected from any one or more selected from the group consisting of aluminum, polyester, polyethylene, polyvinyl acetate, and polypropylene.
  • the matrix layer contains at least one of a polyacrylic acid polymer, a silicone polymer or a mixture thereof.
  • the rasagiline transdermal patch of the present invention described above has a rasagiline content of 0.1 mg/cm 2 to 2 mg/cm 2 .
  • the above-described rasagiline transdermal patch of the present invention further comprises a protective layer which must be removed before use.
  • the rasagiline transdermal patch of the present invention can effectively prevent or minimize the application of the backing layer material having an oxygen transmission rate of not more than 100 cm 3 /m 2 /24h after being applied to the skin.
  • the evaporation of rasagiline from the backing layer to the atmosphere results in a reduction or loss of rasagiline content in the patch, thus ensuring a sustained therapeutic effect of the transdermal patch.
  • a transdermal patch is applied to the surface of the skin to allow the drug to be absorbed through the skin for use in a dosage form for the treatment of systemic diseases and local skin diseases.
  • Conventional transdermal patches are composed of three basic components: a backing layer, a drug-containing layer and a protective layer. In use, the protective layer is removed, the patch is attached to the medication site, and the backing layer serves as a support patch. The role of attachment.
  • Conventional backing layer materials are generally polyester, polyethylene, polyethylene vinylidene chloride copolymer, polyurethane, non-woven fabric, etc. (Modern pharmaceutical preparation technology series: new dosage forms for transdermal administration, People's Health Publishing House, Zheng Junmin Editor-in-Chief, 329 pages).
  • Transdermal patches are usually applied to the human torso, such as the chest, abdomen, and upper arm.
  • the temperature of these parts is generally around 32 °C (Physiology, Seventh Edition, Zhu Danian Editor, People Health Press, p. 203), therefore, the rasagiline transdermal patch is applied to the human torso, such as the chest, abdomen, and upper arm, at an ambient temperature of about 32 ° C or higher.
  • the Shajilan transdermal patch is exposed to this ambient temperature for a long time, and rasagiline is easily volatilized and volatilized into the atmosphere through the backing layer, thereby causing loss of rasagiline content and affecting the continuous therapeutic effect.
  • the inventors After long-term research, the inventors have found that when the oxygen permeability of the backing layer material is not more than 100 cm 3 /m 2 /24h, the rasagiline can be effectively prevented or reduced from being volatilized into the atmosphere through the backing layer. Maintain a continuous therapeutic effect.
  • the backing layer material used in the rasagiline transdermal patch of the present invention has an oxygen transmission rate of not more than 100 cm 3 /m 2 /24h, and rasagiline made of a backing layer material conforming to this characteristic
  • the patch at ambient temperatures around 32 ° C, effectively reduces the loss of rasagiline volatilization to an acceptable level (5%).
  • the moisture permeability of backing materials generally has a greater impact on the loss of volatile substances (Modern Pharmaceutical Preparation Technology Series: New Formulations for Transdermal Drug Delivery, People's Medical Publishing House, Zheng Junmin, 329 pages), but for the rasagiline transdermal patch, the moisture transmission rate has little effect on the volatile loss of rasagiline, and it is not the main factor affecting the volatile loss of rasagiline.
  • the moisture permeability of the backing materials Scotchpak 9723 and Scotchpak 9732 was higher than that of the comparative example, and the volatile loss of rasagiline was much smaller than that of the comparative example.
  • the present inventors have unexpectedly discovered that the oxygen transmission rate of the backing layer has a greater influence on the volatilization loss of rasagiline.
  • Table 1 The characteristics of the backing material used in the examples are shown in Table 1:
  • Scotchpak9723 Polyethylene-polyester composite film 1.66 10 100
  • the rasagiline transdermal patch of the present invention has a backing layer material having an oxygen transmission rate of not more than 100 cm 3 /m 2 /24h, for different materials, by increasing the thickness of the film or Is to increase the density, such as using high-density polyethylene film instead of low-density polyethylene film, or compounding a material with low oxygen transmission rate, such as aluminum layer, on a film with high oxygen permeability, as long as A gas permeability of not more than 100 cm 3 /m 2 /24h can be used as the backing layer material of the transdermal patch of the present invention to reduce the volatile loss of rasagiline.
  • the rasagiline transdermal drug patch of the present invention wherein the substrate is an organic polymer material, including a polyacrylic acid polymer, a silicone polymer or a mixture thereof.
  • the commonly used organic high molecular polymer materials for the patch are polyisobutylene polymer, polyacrylic acid polymer and silicone polymer, which are often used as pressure sensitive adhesive materials for the patch, so that the patch can be adhered to the surface of the skin. At the same time, they can also be used as a drug carrier to slowly release the drug.
  • the polyisobutylene polymer has low water vapor permeability, moisture permeability and oxygen permeability. When the polyisobutylene polymer is attached to the skin for a long time, water accumulation occurs, and the skin is whitened. Polyisobutylene is only suitable for low water. Solubility and low polarity drugs. Due to the non-polar nature of the polyisobutylene, it is weak to the polar substrate.
  • Polyacrylic acid polymer has excellent adhesion, aging resistance, light resistance and water resistance, and has a great progress in water vapor transmission compared with polyisobutylene polymer. It is a preferred matrix material for the present invention, such as the US National Starch Chemical Co., Ltd. Company (National Starch & Chemical Co.) DRUO-TAK series of polyacrylic acid polymers, such as DRUO-TAK4098,
  • the silicone polymer has strong wetting ability as a substrate and is suitable for surface coating of various substrates. Due to the flexibility of the molecular chain, the molecular chain base has a large gap, and the permeability of water vapor and drug molecules is good. It has excellent biological properties, such as non-toxic, non-allergenic, biocompatible, good permeability to [multi-drugs, etc., and is also a preferred matrix material for the present invention, such as Dow Corning Co., USA.
  • the rasagiline transdermal patch of the present invention is characterized in that: the patch backing layer material has an oxygen permeability of 2.0 cm 3 /m 2 /24h, and the patch substrate is polyacrylic acid.
  • the polymer after being placed at 32 ° C for four days, its content changed from 98.4% to 98.3% at 0 days, with substantially no change.
  • the rasagiline transdermal patch of the present invention is characterized in that: the patch backing layer material has an oxygen transmission rate of 100 cm 3 /m 2 /24h, and the patch substrate is polyacrylic acid.
  • the polymer after standing at 32 ° C for four days, its content changed from 97.9% of 0 days to 97.1%, with substantially no change.
  • the rasagiline transdermal patch of the present invention is characterized in that: the patch backing layer material has an oxygen transmission rate of 80 cm 3 /m 2 /24 h, and the patch substrate is a polyacrylic acid polymerization. After being placed at 32 ° C for four days, the content changed from 98.6% at 0 days to 94.3%, and the content decreased within 5%.
  • the rasagiline transdermal patch of the present invention is characterized in that: the patch backing layer material has an oxygen transmission rate of 20 cm 3 /m 2 /24 h, and the patch substrate is a polyacrylic acid polymerization. After being placed at 32 ° C for four days, the content was changed from 99.5% of 0 days to 99.2%, and the content fell within 5%.
  • the patch backing layer material has an oxygen transmission rate of 3840 cm 3 /m 2 /24 h
  • the patch substrate is a polyacrylic acid polymer, which is placed at 32 ° C for four days. The content changed from 98.0% in 0 days to 27.5%, and the content decreased significantly.
  • the patch backing layer material has an oxygen transmission rate of 6400 cm 3 /m 2 /24 h
  • the patch substrate is a polyacrylic acid polymer, and after being placed at 32 ° C for four days, Its content changed from 99.6% of 0 days to 19.2%, and the content decreased significantly.
  • the rasagiline transdermal patch of the present invention is characterized in that: the patch backing layer material has an oxygen permeability of 2.0 cm 3 /m 2 /24h, and the patch substrate is silicone. Polymer, at 32 ° C After being placed for four days, the content changed from 103.8% in 0 days to 101.9%, and there was almost no change.
  • the rasagiline transdermal patch of the present invention is characterized in that: the patch backing layer material has an oxygen transmission rate of 100 cm 3 /m 2 /24 h, and the patch substrate is silicone polymerization. After being placed at 32 ° C for four days, the content changed from 96.3% at 0 days to 98.5%, with almost no change.
  • the rasagiline transdermal patch of the present invention is characterized in that: the patch backing layer material has an oxygen permeability of 80 cm 3 /m 2 /24 h, and the patch substrate is silicone polymerization. After being placed at 32 ° C for four days, the content changed from 96.9% of 0 days to 94.1%, and the content fell within 5%.
  • the rasagiline transdermal patch of the present invention is characterized in that: the patch backing layer material has an oxygen permeability of 20 cm 3 /m 2 /24h, and the patch substrate is silicone.
  • the polymer after being placed at 32 ° C for four days, its content changed from 98.7% on day 0 to 97.4%, and the content decreased within 5%.
  • the patch backing layer material has an oxygen transmission rate of 3840 cm 3 /m 2 /24 h
  • the patch substrate is a silicone polymer, which is placed at 32 ° C for four days. The content changed from 97.4% in 0 days to 33.9%, and the content decreased significantly.
  • the patch backing layer material has an oxygen transmission rate of 6400 cm 3 /m 2 /24 h, and the patch substrate is a silicone polymer, and after being placed at 32 ° C for four days, The content changed from 98.2% in 0 days to 16.7%, and the content decreased significantly.
  • Example 1 Scotchpakl l09 backing, patch based on polyacrylic polymer polymer ⁇
  • BIO-PSA4302 pressure sensitive adhesive 10g Preparation:
  • the substrate is a patch of polyacrylic acid polymer and silicone polymer.
  • the rasagiline content is less than 5% due to volatilization into the atmosphere through the backing, prevention or maximum
  • the rasagiline volatilization loss is reduced to ensure product quality and continuous therapeutic effect.
  • a transdermal patch for preventing rasagiline volatilization proposed by the present invention has been described by way of example, and it is apparent to those skilled in the art that the prevention of rasagigi described herein can be made without departing from the spirit, scope and scope of the present invention.
  • the blue volatilized transdermal patches are modified or modified and combined to achieve the techniques of the present invention. It is to be understood that all such alternatives and modifications are obvious to those skilled in the art and are considered to be included in the spirit, scope and content of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un timbre transdermique de rasagiline qui comprend de la rasagiline ou des sels pharmaceutiquement acceptables de celle-ci, une substance de base et une couche de support inerte. La transmittance d'oxygène de la couche de support n'est pas supérieure à 100 cm3/m2/24h，qui peut réduire efficacement la volatilisation de la rasagiline depuis la couche de support qui conduit à une teneur réduite, par conséquent un effet de traitement prolongé à long terme est assuré.
PCT/CN2011/083040 2010-11-29 2011-11-28 Timbre transdermique prévenant la volatilisation de la rasagiline WO2012072014A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010105622173A CN102475692A (zh) 2010-11-29 2010-11-29 一种防止雷沙吉兰挥发的透皮贴片
CN201010562217.3 2010-11-29

Publications (1)

Publication Number Publication Date
WO2012072014A1 true WO2012072014A1 (fr) 2012-06-07

Family

ID=46088550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/083040 WO2012072014A1 (fr) 2010-11-29 2011-11-28 Timbre transdermique prévenant la volatilisation de la rasagiline

Country Status (2)

Country Link
CN (1) CN102475692A (fr)
WO (1) WO2012072014A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103851C2 (en) 2010-04-30 2013-11-25 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Propylaminoindan transdermal composition
EP2688561B1 (fr) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Compositions transdermiques comprenant une couche d'agent actif et une couche de conversion d'agent actif
EA031621B1 (ru) 2012-11-02 2019-01-31 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Трансдермальная композиция на основе пропиниламиноиндана, содержащий такие композиции набор и способ доставки пропиниламиноиндана

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032474A (zh) * 2006-03-06 2007-09-12 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CN101606923A (zh) * 2008-06-20 2009-12-23 重庆医药工业研究院有限责任公司 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1256340T1 (en) * 2001-05-08 2003-12-31 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032474A (zh) * 2006-03-06 2007-09-12 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CN101606923A (zh) * 2008-06-20 2009-12-23 重庆医药工业研究院有限责任公司 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法

Also Published As

Publication number Publication date
CN102475692A (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
JP5564469B2 (ja) ロチゴチン投与のための改善された経皮送達系
JP4511691B2 (ja) 経皮的投与のためのマトリックスパッチ
US8246979B2 (en) Transdermal delivery system for the administration of rotigotine
JP4925823B2 (ja) プラミペキソール活性剤を含む経皮治療システム
US8246980B2 (en) Transdermal delivery system
JP6132407B2 (ja) ドネペジルを含有する経皮吸収製剤及びその製造方法
TWI632923B (zh) 用於經皮傳遞安非他命（ａｍｐｈｅｔａｍｉｎｅ）之組合物及方法
CZ302169B6 (cs) Transdermální terapeutický systém s neutralizovanými akrylátovými adhezivními lepidly
JPH0579646B2 (fr)
WO2015200472A1 (fr) Système d'administration transdermique
US8852628B1 (en) Transdermal drug delivery system for diclofenac
JP4874486B2 (ja) 気管支拡張剤ツロブテロールを皮膚から投与するための塩酸ツロブテロールを含む経皮治療システム
EP2697492B1 (fr) Timbres transdermiques à polymères réticulés par faisceau ionisé et caractéristiques de libération améliorée
KR101016914B1 (ko) 향상된 경피 송달 시스템
WO2012072014A1 (fr) Timbre transdermique prévenant la volatilisation de la rasagiline
WO2021098791A1 (fr) Timbre transdermique contenant de la mémantine
JP2001512428A (ja) 伸長性のある経皮治療システム
JP2008208084A (ja) ニコチン徐放性貼付剤
JP2007520480A (ja) 少なくとも一つの脂肪酸を含むジヒドロピリジンタイプのカルシウムアンタゴニスト用の経皮的デリバリー器具
KR100439659B1 (ko) 툴로부테롤을 함유하는 경피흡수용 패취제
CZ50997A3 (en) Transdermal therapeutic system and process for preparing thereof
JP2005529150A (ja) 気管支拡張薬を有するマトリックスタイプパッチ
WO2011150239A2 (fr) Timbres matriciels contenant du piroxicam et procédés pour le traitement topique de la douleur aiguë et chronique et de l'inflammation utilisant lesdits timbres
JP2000505071A (ja) 人体への１７―β―エストラジオールの放出のための皮膚貼着製剤、特に経皮性治療システム
JPS6212725A (ja) 外用医薬製剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11844604

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11844604

Country of ref document: EP

Kind code of ref document: A1